Opus Genetics doses first patient in Phase 1/2 trial of OPGx-LCA5 in patients diagnosed with LCA5
September 11th 2023According to the company, OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies.
Orbis celebrates 20 Years of Cybersight telemedicine platform, new app
September 5th 2023According to the company, the tool provides free access to training and mentors for eye care professionals in areas with the greatest need, and the new Cybersight mobile app expands access for eye care professionals through offline functionality.
Prevent Blindness declares September as Sports Eye Safety Month
September 1st 2023Prevent Blindness plans to educate the public on the risk of significant eye injuries and the need for the proper sports eye protection, with more than 32,000 sports-related eye injuries treated in 2022, up almost 20 percent from previous year.